SLITRK2: A Protein Regulating T-Cell Development and Function

Target Name: SLITRK2

NCBI ID: G84631

SLITRK2

SLITRK2: A Protein Regulating T-Cell Development and Function

SLITRK2 (CXorf1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and liver. It is a member of the T-cell receptor (TCR) family, which is a group of proteins that play a critical role in the immune system. SLITRK2 is known for its ability to regulate the activity of T-cells, which are a crucial part of the immune system.

One of the key functions of SLITRK2 is its role in regulating the development and function of T-cells. T-cells are a critical part of the immune system, as they help to protect the body against infection and disease. They are produced in the bone marrow and are a part of the adaptive immune system, which is the system that learns and adapts to an ongoing attack by the immune system.

SLITRK2 plays a key role in the regulation of T-cell development and function. It is known to be involved in the development of T-cells from the hematopoietic stem cell (HSC), which is a type of stem cell that gives rise to all of the different blood cells in the body. SLITRK2 is also involved in the regulation of the stem cell niche, which is the environment in which stem cells divide and grow.

In addition to its role in T-cell development, SLITRK2 is also known to be involved in the regulation of T-cell function. It is a negative regulator of the T-cell receptor (TCR), which is a protein that is responsible for recognizing and responding to foreign substances in the body. SLITRK2 helps to prevent the TCR from functioning at its full capacity, which is necessary for the T-cell to be able to recognize and respond to foreign substances.

The discovery of SLITRK2 as a potential drug target or biomarker has significant implications for the development of new treatments for a variety of diseases. For example, if SLITRK2 is found to be a drug target, researchers may be able to develop new treatments for diseases that are caused by the overactive or dysfunctional activity of T-cells, such as cancer, autoimmune diseases, and infections. In addition, if SLITRK2 is found to be a biomarker, it may be used as a diagnostic tool for diseases that are characterized by the overactive or dysfunctional activity of T-cells.

SLITRK2 is also of interest to researchers studying the role of T-cells in the development and progression of diseases. For example, studies have shown that T-cells play a key role in the development of cancer, and that their dysfunction can contribute to the development of cancer. By studying the role of SLITRK2 in T-cell development and function, researchers may be able to gain insights into the mechanisms that drive T-cell dysfunction and cancer development.

Overall, SLITRK2 is a protein that is expressed in various tissues throughout the body and is known for its role in the regulation of T-cell development and function. Its potential as a drug target or biomarker has significant implications for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of SLITRK2 in the immune system and its potential as a drug or biomarker.

Protein Name: SLIT And NTRK Like Family Member 2

Functions: It is involved in synaptogenesis and promotes excitatory synapse differentiation (PubMed:27273464, PubMed:27812321). Suppresses neurite outgrowth (By similarity)

The "SLITRK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLITRK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets